# **Title:** *BCKDK* **rs14235 A allele is associated with milder motor impairment and altered network topology in Parkinson's disease**

Authors: Zhichun Chen<sup>1,2</sup>, Bin Wu<sup>3</sup>, Guanglu Li<sup>1</sup>, Liche Zhou<sup>1</sup>, Lina Zhang<sup>4</sup>, and Jun Liu<sup>1\*</sup> <sup>1</sup>Department of Neurology and Institute of Neurology, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China

<sup>2</sup>Department of Neurology, The Second Xiangya Hospital, Central South University, 139 Renminzhong Road, Changsha, 410011, China

<sup>3</sup>Department of Neurology, Xuchang Central Hospital affiliated with Henan University of Science and Technology, Henan, 461000, China

<sup>4</sup>Department of Biostatistics, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China

**\*Correspondence:** Jun Liu, Department of Neurology and Institute of Neurology, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. E-mail address: jly0520@hotmail.com (J. Liu).

### **Abstract**

**Background** A multitude of genetic variants confer a risk of Parkinson's disease (PD), however, whether these risk variants affected the motor symptoms of PD patients remain largely elusive. The objective of this study is to investigate the effects of *BCKDK* rs14235  $(G > A)$ , a risk variant associated with PD risk, on the motor manifestations and brain networks of PD patients.

**Methods** PD patients (n = 146) receiving magnetic resonance imaging from Parkinson's Progression Markers Initiative (PPMI) database were investigated. The effects of *BCKDK*  rs14235 on the motor manifestations and brain networks of PD patients were systematically evaluated.

**Results** *BCKDK* rs14235 A allele was associated with milder motor symptoms in PD patients. *BCKDK* rs14235 significantly modified the topology of brain structural and functional network. The assortativity in structural network was negatively associated with rigidity in PD while the shortest path length of right pallidum was positively associated with Unified Parkinson's Disease Rating Scale part III (UPDRS-III) scores. The mediation analysis suggested that assortativity in structural network mediated the effects of *BCKDK* rs14235 on rigidity and the shortest path length of right pallidum mediated the effects of *BCKDK*  rs14235 on UPDRS-III scores.

**Conclusions** *BCKDK* rs14235 significantly shaped the motor impairment and network topology of PD patients. Differential network metrics mediated the effects of *BCKDK*  rs14235 on rigidity and UPDRS-III scores of PD patients. Future studies were required to identify the molecular mechanisms underlying the effects of *BCKDK* rs14235 on motor impairment and brain network metrics of PD patients.

**Keywords:** Motor impairment, Parkinson's disease, rs14235, brain networks, graphical analysis.

# **Introduction**

Parkinson's disease (PD) is the most common movement disorder in the world  $\frac{1}{1}$ . Bradykinesia, rigidity, static tremor, postural impairment, and gait disabilities were the typical motor manifestations in PD patients  $<sup>1</sup>$ . Although the loss of dopaminergic neurons was</sup> generally thought to be the major culprit resulting in motor impairment in PD, the

mechanisms underlying the degeneration of dopaminergic neurons remain largely elusive  $1$ . According to previous literature, both environmental and genetic factors contribute to dopaminergic neurodegeneration in PD  $^{2-8}$ , however, the occurrence of PD in most individuals is considered to be idiopathic with an unknown cause. Currently, hundreds of genetic loci conferring a risk of PD have been identified<sup>5,6</sup>, nevertheless, the neural mechanisms underlying the pathophysiology of these risk loci for PD are mainly unknown. Decoding the pathophysiology of PD from the perspective of genetics has recently become the mainstream study area as a result of the identification of new risk loci  $5-7$ . Recently, new research breakthroughs in PD have been driven by the discovery of the biological functions of PD risk genes and their roles in the occurrence and development of PD at molecular, cellular, neural circuit and behavior levels  $9-16$ . Over the last decade, a number of genes associated with PD risk, including  $SNCA^{14,17-19}$ ,  $PRKN^{9-12}$ ,  $LRRK2^{20-25}$ ,  $PINKI$ <sup>11-13</sup>, *TMEM175* 16, *GPNMB 26,27*, and *ATP13A2* 15, have been studied, both in terms of physiological and pathological functions. These discoveries have expanded our understanding of the neurodegenerative process in PD and identified key mechanisms by which we can identify potential therapeutic targets.

There is mounting evidence that the clinical characteristics of individuals with PD were diverse and intricate, presenting a significant obstacle to the clinical diagnosis and management in PD patients <sup>28-31</sup>. Previous studies suggest that genetic variations modify age at onset  $32,33$ , influence motor progression  $34-36$ , and alter the frequency of a variety of nonmotor symptoms 37-39. Specifically, a multitude of mutated genes, such as *GBA* 36,38,39, *LRRK2* 24,40,41, *PRKN* 42,43, *PINK1* 43,44, *SNCA* 41,45 have been proven to alter the diverse range of symptoms experienced by individuals with familial PD. Therefore, genetic variations significantly contributed to the clinical heterogeneity of PD patients. For example, it has been shown that individuals harboring *GBA* variants encountered an earlier age at onset and exhibited more pronounced motor and nonmotor symptoms in comparison to individuals without GBA variants <sup>46,47</sup>. According to previous studies, the motor impairment of PD patients were linked to several variants, including *GBA* 46,47, *SNCA* 48,49, *BST1* 50, *ATP8B2* 51, *PARK16*<sup>52</sup>, *GCH1*<sup>53</sup>, and *APOE*<sup>54</sup>. Recently, we revealed 3 PD-risk associated genetic variants, *BCKDK* rs14235, *CCDC62* rs11060180, and *GCH1* rs11158026, were significantly associated with motor function, which was measured by Unified Parkinson's Disease Rating Scale part III (UPDRS-III), in PD patients from Parkinson's Progression Markers Initiative (PPMI) database <sup>55</sup>. In fact, the effects of *GCH1* rs11158026 on motor decline of PD patients

have been demonstrated by a previous study  $53$ . These findings suggested that the motor manifestations of PD patients were significantly shaped by genetic variations. However, the neural mechanisms underlying the effects of these genetic variants on motor function remain largely unknown. We have recently demonstrated that motor and nonmotor symptoms in PD patients were significantly related to brain structural and functional network metrics 37,55,56. Additionally, we have shown that the effect of *MAPT* rs17649553 on PD patients' verbal memory was mediated by the small-worldness metrics of white matter network  $37$ . Furthermore, we also reported that the effects of *CCDC62* rs11060180 on motor function of PD patients were mediated by the small-world topology in gray matter covariance network  $^{55}$ . Hence, PD risk-associated genetic variants may shape the motor and non-motor symptoms by influencing the structural and functional networks of PD patients  $37,55$ .

*BCKDK* rs14235 (G > A) was associated with increased PD risk  $5.6$  and significantly modified the motor function of PD patients <sup>55</sup>. In this study, we reasoned that *BCKDK* rs14235 may also modify brain network metrics and network metrics shaped by *BCKDK*  rs14235 may mediate the effects of *BCKDK* rs14235 on motor function. Therefore, the objective of current study is to evaluate whether *BCKDK* rs14235 affects the structural and functional brain networks of PD patients and to examine whether network metrics shaped by *BCKDK* rs14235 mediate its associations with motor impairment of PD patients. Specifically, our goals consist of: (i) investigate whether *BCKDK* rs14235 A allele is associated scores of motor assessments in PD patients using association analysis; (ii) examine whether structural and functional network measurements vary significantly between GG carriers and A-carriers (GA and AA carriers); (iii) assess whether the effects of *BCKDK* rs14235 on graphical network metrics were independent of common confounding variables, such as age, sex, and disease duration; and (iv) evaluate whether the structural network and functional network measurements mediate the impacts of *BCKDK* rs14235 on motor function of PD patients.

# **Materials and Methods**

#### **Participants**

The data used in this study were acquired from PPMI cohort study. The PPMI study was approved by Institutional Review Board of each participating site. The informed consents were signed from all participants and could be obtained from the investigators of each participating site. The PD patients were included if they met the criteria below: (i) The patients aged over 30 years old and had a disease duration within 2 years; (ii) The patients had a diagnosis of PD according to the Movement Disorders Society (MDS) Clinical Diagnostic Criteria for PD; (iii) The patients received 3D T1-weighted MPRAGE imaging, resting-state fMRI imaging, and diffusion tensor imaging (DTI) during the same period; (iv) The PD patients received motor assessments including Hoehn and Yahr (H&Y) stages, tremor scores, rigidity scores, and the MDS Unified Parkinson's Disease Rating Scale part III (MDS-UPDRS). The PD patients were excluded if they met the exclusion criteria below: (i) The patients showed structural abnormalities in the T1-weighted or T2-weighted MRI; (ii) The patients were diagnosed to have PD dementia or dementia with Lewy bodies based on the MDS criteria; (iii) The patients were found to carry the genetic mutations of familial PD or were from the genetic PPMI cohort and prodromal cohort. Finally, one hundred and fortysix PD patients receiving DTI images ( $n = 146$ ) were included in this study. Among these patients, eighty-three of them  $(n = 83)$  also underwent functional MRI. To decipher the associations between *BCKDK*  $rs14235$  ( $G > A$ ) and motor assessments or brain network metrics, the whole-exome sequencing of blood DNA samples was performed to obtain the genotypes of *BCKDK* rs14235 for individual participant. The demographic and clinical characteristics in different genotype groups (CC carriers, CT carriers, TT carriers) of *BIN3* rs2280104 were compared and shown in Table 1.

# **Image acquisition**

The 3D T1-weighted MRI images, resting-state functional images, and DTI images were acquired using 3T Siemens (TIM Trio and Verio) scanners (Erlangen, Germany). The MRI parameters for 3D T1 images were shown below:  $TR = 2300$  ms,  $TE = 2.98$  ms, Voxel size = 1 mm<sup>3</sup>, Slice thickness =1.2 mm, twofold acceleration, sagittal-oblique angulation. The DTI was performed with the parameters as follows: TR=  $8,400-8,800$  ms, TE =  $88$  ms, Voxel size  $= 2$  mm<sup>3</sup>, Slice thickness  $= 2$  mm, 64 directions, b  $= 1000$  s/mm<sup>2</sup>. The resting-state functional images were performed using a T2\*-weighted echo planar imaging (EPI) sequence as shown below: TR = 2400 ms, TE = 25 ms, Voxel size = 3.3 mm<sup>3</sup>, Slice number = 40, Slice thickness  $= 3.3$  mm, Flip angle  $= 90^{\circ}$ , Acquisition time  $= 8$  min.

### **Imaging preprocessing**

The DTI images were preprocessed using FMRIB Software Library toolbox (FSL, https://fsl.fmrib.ox.ac.uk/fsl/fslwiki). Briefly, DTI images were corrected for head motions, eddy current distortions, and susceptibility artifacts resulted from magnetic field inhomogeneity. The fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity, and radial diffusivity maps were computed according to the methods as previously reported. The processed images were then reconstructed in standardized MNI space for the following structural network construction.

The SPM12 (http://www.fil.ion.ucl.ac.uk/spm/software/spm12/) and GRETNA software (https://www.nitrc.org/projects/gretna/) were utilized for the preprocessing of resting-state functional images. The detailed preprocessing procedures for functional images included: slice-timing correction, spatial normalizing with standard EPI template, spatial smoothing with 4-mm Gaussian kernel, removal of nuisance signals, and temporal bandpass filtering  $(0.01-0.1 \text{ Hz})$ . The participants (n = 9) with head motion frame-wise displacement (FD) > 0.5 mm and head rotation  $> 2^{\circ}$  were excluded due to excessive head motions according to previous studies 57-60. In addition, the head motion parameters were adjusted to correct the effects of head motions on the functional images. Furthermore, we also guaranteed that there were no significant differences in FD values between the GG carriers and T-carriers of *BCKDK* rs14235 (*p* > 0.05).

# **Network construction**

As previously reported  $37,56$ , the white matter network was constructed using deterministic fiber tractography implemented in PANDA (http://www.nitrc.org/projects/panda/), a free and open MATLAB software. The Fiber Assignment by Continuous Tracking (FACT) algorithm was utilized to derive the whole-brain white matter fibers between each pair of 90 nodes in the AAL atlas. The threshold for mean FA skeleton was set to  $FA > 0.20$  and the threshold for white matter fiber angle was set to  $45^\circ$ . As a result, fiber number-based white matter network matrices were constructed in conformity with AAL atlas.

 The steps for the construction of functional connectivity matrices were as follows. Firstly, AAL atlas was used to define 90 cortical and subcortical nodes in functional network. Secondly, Pearson correlation coefficient was computed for the time series of 90 nodes to represent the pairwise function connectivity. Finally, the correlation coefficients in functional connectivity matrices were Fisher's r-to-z transformed to improve the normality of functional connectivity.

#### **Graph-based network analysis**

The GRETNA (https://www.nitrc.org/projects/gretna/) linked with MATLAB software was sued to calculate the graphical network metrics of structural and functional  $^{61}$ . During the

calculation of global and nodal network metrics, a range of network sparsity thresholds (0.05  $\sim$  0.50 with an interval of 0.05) were established. The area under curve (AUC) of global and nodal network metrics was also computed. The global network characteristics consisted of: assortativity, hierarchy, global efficiency, local efficiency, and small-worldness metrics. The small-worldness metrics consisted of: clustering coefficient (Cp), characteristic path length (Lp), normalized clustering coefficient (γ), normalized characteristic path length ( $\lambda$ ), and small worldness (σ). The nodal network characteristics include: nodal betweenness centrality, nodal degree centrality, nodal Cp, nodal efficiency, nodal local efficiency, and nodal shortest path length (SPL). The definitions of the aforementioned network metrics have been reported by previous investigations  $55,62,63$ .

### **Statistical analysis**

### **Comparison of clinical variables**

For comparisons of continuous variables, unpaired t-test (GG carriers vs A-carriers) and oneway ANOVA test followed by false discovery rate (FDR) correction (GG carriers vs GA carrier vs AA carriers) were used. For comparisons of categorical variables,  $\chi^2$  test was used. *p* < 0.05 was considered statistically significant.

# **Comparison of global network strength**

Network-Based Statistic (NBS, https://www.nitrc.org/projects/nbs/) software was used to compare the global network strength of structural and functional networks in different genotype groups of *BCKDK* rs14235<sup>64</sup>. The covariates, including age, sex, years of education, and disease duration were included during NBS analysis.  $p < 0.05$  after FDR correction was considered statistically significant <sup>65</sup>.

### **Comparison of network metrics**

Two-way ANOVA test followed by FDR corrections was used for the comparisons of global and nodal network metrics among different genotype groups of *BCKDK* rs14235. *p* < 0.05 after FDR correction was considered statistically significant. The AUCs of global network metrics among different genotype groups of *BCKDK* rs14235 were compared using one-way ANOVA test followed by FDR corrections.  $p < 0.05$  was considered statistically significant.

### **Association analysis between genotype and scores of motor assessments**

The Pearson correlation and multivariate regression analysis were used to analyze the associations between genotype of *BCKDK* rs14235 and scores of motor assessments. During the multivariate regression analysis, age, sex, disease duration, and years of education were included as covariates.  $p < 0.05$  was considered statistically significant.

### **Association analysis between genotype and graphical network metrics**

The multivariate regression analysis was utilized to analyze the associations between genotype of *BCKDK* rs14235 and graphical network metrics with age, sex, disease duration, and years of education as covariates. FDR-corrected  $p < 0.05$  was considered statistically significant.

# **Association analysis between graphical metrics and scores of motor assessments**

The Pearson correlation and multivariate regression analysis were used to analyze the associations between graphical metrics and scores of motor assessments. Age, sex, disease duration, and years of education were included as covariates during multivariate regression analysis.  $p < 0.05$  was considered statistically significant.

# **Mediation analysis**

IBM SPSS Statistics Version 26 was used to perform mediation analysis. The independent variable in the mediation model was the genotype of *BCKDK* rs14235. The dependent variables were the scores of rigidity or UPDRS-III. The mediators were graphical network metrics associated with scores of motor assessments. We modeled the mediated effects of graphical network metrics on the relationships between scores of motor assessments and genotype of *BCKDK*. During the mediation analysis, the age, sex, disease duration, and years of education were included as covariates.  $p < 0.05$  was considered statistically significant.

# **Results**

# **Allele and genotype frequencies**

The allele frequencies (G allele frequency  $= 0.5993$ , A allele frequency  $= 0.4007$ ) for *BCKDK* rs14235 were comparable to the data from Allele Frequency Aggregator Project (A allele frequency  $= 0.3798$ ). The distribution of genotype frequencies from our patients didn't deviate Hardy–Weinberg equilibrium (*p* > 0.10). Genotype frequencies were similar with respect to age or sex ( $p > 0.05$ ).

# **Group difference of clinical variables and multivariate regression analysis**

The group differences of clinical variables in different genotype groups of *BCKDK* rs14235 were shown in Table 1 and Figure 1. The Hoehn & Yahr stages and tremor scores were not statistically different between GG carriers and A-carriers (GA carriers and AA carriers). The rigidity scores and UPDRS-III scores were significantly lower in A-carriers compared to GG carriers (Table 1 and Figure 1). Consistently, the rigidity scores and UPDRS-III scores in GA carriers and AA carriers were also much lower than those of GG carriers (Table 1 and Figure 1). The *BCKDK* rs14235 A allele was negatively associated with rigidity scores (β = -1.0410, *p* < 0.01) and UPDRS-III scores ( $\beta$  = -3.3540, *p* < 0.01).

#### **Group difference of graphical network metrics in structural network**

Compared to GG carriers and GA carriers, AA carriers exhibited higher assortativity (FDRcorrected  $p < 0.05$ , sparsity range:  $0.10 - 0.50$ ; Figure 2A). Compared to GG carriers, AA carriers had lower small-worldness  $\gamma$  and  $\sigma$  (FDR-corrected  $p < 0.05$ , sparsity range: 0.15,0.30, 0.45-0.50; Figure 2A-C). Consistently, we also found higher AUC of assortativity in AA carriers compared to GG carriers and GA carriers (FDR-corrected  $p < 0.05$ ; Figure S1A). Additionally, AA carriers exhibited lower AUCs of small-worldness  $\gamma$  and  $\sigma$  compared to GG and GA carriers (FDR-corrected  $p < 0.05$ ; Figure S1B-C). For nodal metrics, AA carriers exhibited lower betweenness centrality in bilateral calcarine, left precuneus, and left thalamus compared to GG and GA carriers (FDR-corrected  $p < 0.05$ ; Figure 2D). Compared to GG carriers, GA and AA carriers showed higher betweenness centrality, degree centrality, and nodal efficiency in right precuneus (FDR-corrected  $p < 0.05$ ; Figure 2D, E, G). In addition, some key nodes in basal ganglia network, such as left putamen, right putamen, right pallidum also showed differential nodal network metrics among different genotype groups of *BCKDK* rs14235 (FDR-corrected  $p < 0.05$ ; Figure 2D, E, G, I). Interestingly, AA carriers showed higher nodal Cp, nodal efficiency, and nodal local efficiency in right heschl compared to GG and GA carriers (FDR-corrected  $p < 0.05$ ; Figure 2F-H).

#### **Group difference of graphical network metrics in functional network**

Compared to GG carriers, GA and AA carriers exhibited higher global efficiency (FDRcorrected *p* < 0.05, sparsity range: 0.10-0.20; Figure 3A) and local efficiency (FDR-corrected  $p < 0.05$ , sparsity range:  $0.05$ -0.15; Figure 3B) at multiple sparsity thresholds. In agreement with this, the AUCs of global efficiency and local efficiency were also higher in GA and AA carriers compared to GG carriers (FDR-corrected  $p < 0.05$ ; Figure S1D-E). For nodal network metrics, AA carriers showed higher betweenness centrality in right middle fontal gyrus, right posterior cingulate gyrus, and bilateral precuneus compared to GA and GG

carriers (FDR-corrected  $p < 0.05$ ; Figure 3C). Moreover, AA carriers had higher degree centrality in right superior orbitofrontal gyrus and right posterior cingulate gyrus compared to GG and GA carriers (FDR-corrected *p* < 0.05; Figure 3D). Interestingly, network metrics of key nodes in basal ganglia network, including right caudate, left caudate, and right putamen were specifically modified by *BCKDK*  $rs14235$  (FDR-corrected  $p < 0.05$ ; Figure 3E-H). Furthermore, AA carriers exhibited higher nodal efficiency in bilateral posterior cingulate gyrus compared to GG carriers, companied by lower nodal SPL in AA carriers compared to GG carriers (FDR-corrected *p* < 0.05; Figure 3E and H). Taken together, these data supported that *BCKDK* rs14235 A allele enhanced the nodal network metrics of functional networks in PD.

#### **The associations between** *BCKDK* **rs14235 and graphical network metrics**

To examine whether the effects of *BCKDK* rs14235 on graphical network metrics were independent of common confounding variables, multivariate regression analysis was used to assess the associations between *BCKDK* rs14235 and graphical network metrics showing statistical group difference in Figure 2-3. As shown in Table S1 and Table S2, *BCKDK*  rs14235 was significantly associated with multiple brain network metrics in both structural and functional networks (FDR-corrected  $p < 0.05$ ; Table S1 and Table S2). These results demonstrated that *BCKDK* rs14235 independently shaped the network topology of both structural and functional network.

### **Mediation analysis**

To explore whether graphical network metrics contributed to the effects of *BCKDK* rs14235 on motor impairment of PD patients, we analyzed the associations between graphical network metrics and rigidity scores or UPDRS-III scorers. Among those metrics showing significant group differences, AUC of assortativity in structural network was negatively associated with scores of rigidity ( $\beta$  = -1.29,  $p < 0.05$ ; Figure 4A) while nodal SPL of right pallidum in structural network was positively associated with scores of UPDRS-III ( $\beta = 29.23$ ,  $p < 0.01$ ; Figure 4B). With mediation analysis, we further demonstrated that increased AUC of assortativity in structural network mediated the effects of *BCKDK* rs14235 on rigidity (Figure 4C). Additionally, lower nodal SPL in right pallidum in structural network mediated the effects of *BCKDK* rs14235 on UPDRS-III scores (Figure 4D).

# **Discussion**

In this study, we revealed that a PD-associated risk variant, *BCKDK* rs14235, was outstandingly associated with scores of rigidity and UPDRS-III. In addition, *BCKDK* rs14235 prominently affected the network metrics of structural and functional network. Furthermore, differential structural network metrics were correlated with rigidity scores and UPDRS-III scores, respectively. Finally, we demonstrated that it was the increased AUC of assortativity and lower nodal SPL in right pallidum in structural network respectively mediated the effects of *BCKDK* rs14235 on rigidity scores and UPDRS-III scores.

#### **The effects of** *BCKDK* **rs14235 on motor decline of PD patients**

There is increasing consensus that PD is a neurodegenerative disorder with heterogeneous motor and non-motor features  $28-31$ . According to previous literature, the heterogeneity of clinical manifestations was associated with age  $56,666$ , sex  $56,666$ , life styles  $28,67,68$ , genetic variations  $32,38,44,69$ , β-amyloid deposition  $70$ , tau accumulation  $70,71$ , varied pathological spread of synucleinopathy  $^{28,70}$  and diverse degenerative thresholds  $^{28,72}$ . Genetic variations play an essential role in the modifications of clinical phenotypes of PD patients. Particularly, numerous mutated genes in PD, such as *GBA* 36,38,39, *LRRK2* 24,40,41, *PRKN* 42,43, *PINK1* 43,44, *SNCA*<sup>41,45</sup> have been demonstrated to significantly shape the clinical heterogeneity of familial PD patients. Motor symptoms of PD patients, on the other hand, were also influenced by genetic variations. It has been previously shown that the motor impairment of PD patients were linked to a series of genetic variants, including *GBA* 46,47, *SNCA* 48,49, *BST1* 50, *ATP8B2* 51, *PARK16* 52, *GCH1* 53, and *APOE* 54. Recently, we identified 3 genetic variants, *CCDC62* rs11060180, *GCH1* rs11158026 and *BCKDK* rs14235, were significantly associated with UPDRS-III scores in 198 PD patients <sup>55</sup>. In current study, we confirmed that *BCKDK* rs14235 A allele was negatively associated with UPDRS-III scores in 146 PD patients. In addition, *BCKDK* rs14235 A allele was also associated with milder rigidity in PD patients, which further supported that *BCKDK* rs14235 specifically modified motor function of PD patients <sup>55</sup>. Interestingly, *BCKDK* rs14235 A allele was not associated with tremor scores, suggesting that the effect of *BCKDK* rs14235 A allele was only limited to parts of motor symptoms, especially rigidity. Previous studies have reported that *GCH1* rs11158026 T allele was associated with the impairment of dopaminergic innervation in striatum, which might help to explain why this allele was associated with higher UPDRS-III scores <sup>53,55</sup>. In contrast, *BCKDK* rs14235 was not found to be associated with striatal binding ratios (SBRs) of bilateral striatum of PD patients <sup>55</sup>, suggesting that the effects of *BCKDK* rs14235 on motor assessments were independent of striatum SBRs. Taken together, we concluded that *BCKDK* rs14235 was a PD risk-associated genetic variant specifically shaping the motor impairment of PD patients.

#### **The effects of** *BCKDK* **rs14235 on structural network metrics**

We found *BCKDK* rs14235 significantly modified the structural network metrics of PD patients. Compared to GG and GA carriers, AA carriers showed higher assortativity. Assortativity represents the tendency of nodes to connect with 'similar' nodes over 'dissimilar' nodes in a network. It has been shown that assortativity determined the robustness of a network to noise. For example, robustness is greatly enhanced in assortative neural networks  $^{73}$ . Additionally, robustness exhibits a noticeable increase as assortativity becomes more positive in gene regulatory networks  $^{74}$ . Furthermore, assortativity was also associated with higher synchronization in complex neuronal network  $^{75}$ . In current study, we found AA carriers with milder motor decline exhibited higher assortativity compared to GG and GA carriers, which suggested that AA carriers might have higher robustness to noise or random attacks due to their higher network assortativity. However, according to previous studies, PD patients seemed to exhibit increased assortativity  $76-78$ , indicating higher assortativity may be associated with worse motor impairment in PD. One explanation for this discrepancy may be that these studies investigated the functional network and structural covariance network but not white matter network, which usually exhibited distinct topological properties compared to functional and structural covariance network  $79-82$ . Smallworld properties have been discovered in a multitude of biological networks, including gene regulatory network  $^{83}$ , microRNA functional networks  $^{84}$ , protein interaction network  $^{85}$ , and neural networks 86. Recently, we found *MAPT* rs17649553 T allele was associated with higher small-worldness properties in structural network and enhanced small-world topology in structural network mediated the effects of *MAPT* rs17649553 T allele on verbal memory of PD patients <sup>37</sup>. In this study, we found AA carriers exhibited lower small-worldness  $\gamma$  and  $\sigma$ compared to GG carriers, indicating that small-world topology of structural network was specifically targeted by PD-associated risk variants  $<sup>55</sup>$ . For nodal network metrics, we found</sup> network metrics of some key nodes in default mode network and basal ganglia network were preferentially modified. Precuneus was a key node in default mode network and was revealed to be impaired in PD patients. For example, precuneus atrophy and hypometabolism has been found in PD patients with isolated apathy  $87$ . The disruption of functional connectivity and blood perfusion in precuneus was also reported by a series of studies  $88-90$ . We found higher betweenness centrality, degree centrality, and nodal efficiency in right precuneus of AA

carriers compared to GG carriers, indicating that local topology in right precuneus was specifically modulated by A allele of *BCKDK* rs14235. We found nodal network metrics in multiple key nodes of basal ganglia network, such as left putamen, right putamen, and right pallidum, were significantly modified, implying that basal ganglia network was preferentially regulated by A allele of *BCKDK* rs14235. Indeed, the alterations of nodal network metrics in putamen and pallidum have been revealed in PD patients  $91,92$ . For instance, remarkable decreases of nodal efficiency have been observed in globus pallidus and putamen of PD patients 92. Recently, we showed that *MAPT* rs17649553 and *BIN3* rs2280104 significantly modified betweenness centrality of left putamen  $37,93$ , which indicated that left putamen was a shared target of PD-associated risk variants. Taken together, our findings demonstrated that structural network metrics were prominently shaped by *BCKDK* rs14235.

# **The effects of** *BCKDK* **rs14235 on functional network metrics**

In addition to structural network, functional network was also significantly affected by *BCKDK* rs14235. We found higher global efficiency and local efficiency in AA and GA carriers compared to GG carriers, which suggested *BCKDK* rs14235 specifically modified network efficiency of functional network. In fact, compared to control participants, network local efficiency was significantly reduced in PD patients  $94,95$ , whereas network global efficiency seemed to be increased in PD patients  $\frac{95,96}{ }$ . Therefore, our findings indicated that *BCKDK* rs14235 might contribute to the disturbances of network efficiency in PD patients. We found nodal metrics in caudate, putamen, precuneus, and posterior cingulate gyrus were significantly modified by *BCKDK* rs14235, which suggested that similar to structural network, *BCKDK* rs14235 also preferentially shaped the local topology of basal ganglia network and default mode network in functional network of PD patients. The alterations of basal ganglia network and default mode network in PD have been demonstrated by several investigations 92,97-100. Thus, *BCKDK* rs14235 specifically shaped PD-related networks, especially basal ganglia network and default mode network. Interestingly, AA carriers showed consistently higher nodal betweenness centrality, degree centrality, nodal Cp, nodal efficiency, nodal local efficiency, and lower nodal SPL compared to GG and GA carriers, which suggested *BCKDK* rs14235 A allele was associated with enhanced functional network topology in comparison with G allele. In a recent study, we found *BIN3* rs2280104 T-carriers exhibited lower nodal Cp, efficiency, local efficiency, and higher shortest path length in left caudate  $93$ . In this study, we found higher nodal Cp, nodal local efficiency and lower nodal SPL in right caudate of AA carriers, which suggested local topology of caudate was

specifically shaped by PD-associated risk variants<sup>93</sup>. Taken together, our findings demonstrated that functional network metrics were also dramatically modified by *BCKDK* rs14235.

#### **The associations between network metrics and scores of motor assessments**

We found structural network metrics were significantly associated with motor assessments of PD patients, indicating that structural network metrics were potential predictors of motor function in PD. In a recent study, we reported 3 genetic variants, *GCH1* rs11158026, *CCDC62* rs11060180, and *BCKDK* rs14235, were significantly correlated with UPDRS-III scores in PD patients  $<sup>55</sup>$ , nevertheless, the neural mechanisms underlying the effects of these</sup> variants on UPDRS-III scores were not identified. According to a previous study, it seemed that *GCH1* rs11158026 T allele contributed to the deterioration of motor function via the disruption of dopaminergic innervation in striatum <sup>53</sup>. For *CCDC62* rs11060180, we have recently demonstrated that small-world topology in gray matter covariance network mediated the effects of *CCDC62* rs11060180 on motor assessments of PD patients <sup>55</sup>. In this study, we showed that the lower nodal SPL of right pallidum, a key node in basal ganglia network, mediated the effects of *BCKDK* rs14235 on UPDRS-III scores. Pallidum, namely globus pallidus, was a core node in basal ganglia network, which played a key role in the occurrence of PD  $^{101,102}$ . In addition, pallidum was also an important target of neuromodulation in PD <sup>103,104</sup>. Furthermore, the reduction of nodal efficiency in pallidum has been reported in PD patients, indicating impaired local information transfer efficiency in PD $^{92}$ . In this study, we found significantly differential nodal network metrics in right pallidum among GG carriers, GA carriers, and AA carriers, characterized by higher nodal degree centrality and nodal efficiency, as well as lower nodal SPL in A-carriers. These results suggested that A-carriers exhibited higher information transfer efficiency in right pallidum compared to GG carriers, which provided reliable explanations at the network level for the negative association between *BCKDK* rs14235 A allele and UPDRS-III scores in PD patients. To summarize, we concluded that *BCKDK* rs14235 A allele delayed motor decline in PD by improving the local information transfer of right pallidum of structural network.

#### **The potential molecular mechanisms underlying the effects of** *BCKDK* **rs14235**

Branched-chain ketoacid dehydrogenase kinase (BCKDK) is a key rate-limiting enzyme catalyzing the oxidation of branched-chain amino acids 105,106. BCKDK was associated with a multitude of diseases, including cancer  $^{105-107}$ , nonalcoholic fatty liver disease  $^{108}$ ,

neurodevelopmental diseases  $^{109-112}$ , heart failure  $^{113,114}$ , and also PD  $^{115,116}$ . In this study, we found a genetic variant of *BCKDK* gene, rs14235 was significantly associated with motor assessments and network topology of PD patients, which suggested that BCKDK or branched-chain amino acid metabolism may be involved in the pathogenesis of PD. According to GTEx database, *BCKDK* rs14235 was associated with differential expressions of multiple genes in brain tissue, including *KAT8*, *ZNF646*, *VKORC1*, and *BCKDK* 55. Dang et al. (2022) revealed that *KAT8* gene was causally associated with PD using dopaminergic neuron-specific eQTL in a mendelian randomization study  $117$ . KAT8 has been shown to regulate PINK1-dependent mitophagy initiation and partially underlined the genetic risk for PD at  $16q11.2$  and *MAPT* H1 loci<sup>118</sup>. Zinc finger (ZNF) gene family has been recently demonstrated to be associated with PD 119, such as *ZNF219* and *ZNF746*, however, whether *ZNF646* conferred a risk of PD remained elusive. *VKORC1* gene has been shown to be associated with ischemic stroke  $120$ , vascular dementia  $121$ , and Alzheimer's disease  $122$ , whereas whether it was also associated with PD was unknown. On the basis of these findings, we concluded that the role of *BCKDK* gene in PD pathogenesis remained largely unknown. Future studies were required to decipher how *BCKDK* rs14235 affected disease risk, motor function, and network topology of PD patients.

### **Strengths and limitations of this study**

In this study, we reported a PD-associated risk variant, *BCKDK* rs14235 was significantly associated with motor assessments and network topology of PD patients. This finding provided potential interpretations for the individual heterogeneity of motor symptoms in PD patients. In addition, our results also suggested that *BCKDK* rs14235 A allele is a genetic predictor of motor function in PD patients. The effects of *BCKDK* rs14235 on structural network and functional network indicated that *BCKDK* rs14235 significantly shaped the topological organizations of brain network. Particularly, *BCKDK* rs14235 A allele enhanced the local information transfer of right pallidum of structural network, which mediated the effects of *BCKDK* rs14235 A allele on motor assessment of PD patients. This provided plausible network mechanisms to explain the effects of *BCKDK* rs14235 A allele on motor decline of PD patients. The limitation of this study was that we did not determine the molecular mechanisms mediating the effects of *BCKDK* rs14235 on motor function and brain networks. Further studies are encouraged to decipher the impact of *BCKDK* rs14235 on PD pathogenesis at the molecular level.

# **Conclusions**

To summarize, we reported a PD risk-associated genetic variant, *BCKDK* rs14235, was significantly associated with motor assessments of PD patients. In addition, we found *BCKDK* rs14235 A allele modified both structural network and functional network. Moreover, we further showed structural network metrics were significantly correlated with motor symptoms. Finally, we demonstrated that it was the local topology of right pallidum that mediated the effects of *BCKDK* rs14235 A allele on motor assessments of PD patients.

### **Author contributions**

Zhichun Chen, Conceptualization, Formal analysis, Visualization, Methodology, Writing original draft, Writing - review and editing; Bin Wu, Validation, Investigation, Methodology; Guanglu Li, Data curation, Formal analysis, Visualization; Liche Zhou, Data curation, Formal analysis, Investigation; Lina Zhang, Formal analysis, Investigation, Methodology; Jun Liu, Conceptualization, Supervision, Funding acquisition, Writing - original draft, Project administration, Writing- review and editing.

# **Acknowledgments**

Data used in the preparation of this article were obtained from the Parkinson's Progression Markers Initiative (PPMI) database (www.ppmiinfo.org/data). We thank the share of PPMI data by all the PPMI study investigators. PPMI – a public-private partnership – is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, which can be found at www.ppmiinfo.org/fundingpartners.

### **Funding information**

This work was supported by grants from National Natural Science Foundation of China (Grant No. 81873778, 82071415) and National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (Grant No. NRCTM(SH)-2021-03).

# **Conflict of Interest**

The authors have no conflict of interest to report.

# **Data availability**

All the raw data used in the preparation of this Article were downloaded from PPMI database (www.ppmi-info.org/data).All data produced in the present study are available upon reasonable request to the authors.

# **Supporting Information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

# **Reference**

- 1. Bloem BR, Okun MS, Klein C. Parkinson's disease. *Lancet.* 2021;397(10291):2284- 2303.
- 2. Dunn AR, O'Connell KMS, Kaczorowski CC. Gene-by-environment interactions in Alzheimer's disease and Parkinson's disease. *Neurosci Biobehav Rev.* 2019;103:73-80.
- 3. Georgiou A, Demetriou CA, Christou YP, et al. Genetic and Environmental Factors Contributing to Parkinson's Disease: A Case-Control Study in the Cypriot Population. *Front Neurol.* 2019;10:1047.
- 4. Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. *Nat Genet.*  2014;46(9):989-993.
- 5. Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet Neurol.* 2019;18(12):1091-1102.
- 6. Chang D, Nalls MA, Hallgrimsdottir IB, et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. *Nat Genet.*  2017;49(10):1511-1516.
- 7. Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. *Nat Genet.*  2009;41(12):1303-1307.
- 8. Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention. *Lancet Neurol.* 2016;15(12):1257-1272.
- 9. Manzanillo PS, Ayres JS, Watson RO, et al. The ubiquitin ligase parkin mediates resistance to intracellular pathogens. *Nature.* 2013;501(7468):512-516.
- 10. Bingol B, Tea JS, Phu L, et al. The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy. *Nature.* 2014;510(7505):370-375.
- 11. Matheoud D, Sugiura A, Bellemare-Pelletier A, et al. Parkinson's Disease-Related Proteins PINK1 and Parkin Repress Mitochondrial Antigen Presentation. *Cell.*  2016;166(2):314-327.
- 12. Sliter DA, Martinez J, Hao L, et al. Parkin and PINK1 mitigate STING-induced inflammation. *Nature.* 2018;561(7722):258-262.
- 13. Matheoud D, Cannon T, Voisin A, et al. Intestinal infection triggers Parkinson's disease-like symptoms in Pink1(-/-) mice. *Nature.* 2019;571(7766):565-569.
- 14. Burmann BM, Gerez JA, Matecko-Burmann I, et al. Regulation of alpha-synuclein by chaperones in mammalian cells. *Nature.* 2020;577(7788):127-132.
- 15. van Veen S, Martin S, Van den Haute C, et al. ATP13A2 deficiency disrupts lysosomal polyamine export. *Nature.* 2020;578(7795):419-424.

- 16. Wie J, Liu Z, Song H, et al. A growth-factor-activated lysosomal K(+) channel regulates Parkinson's pathology. *Nature.* 2021.
- 17. Peng C, Gathagan RJ, Covell DJ, et al. Cellular milieu imparts distinct pathological alpha-synuclein strains in alpha-synucleinopathies. *Nature.* 2018;557(7706):558-563.
- 18. Fusco G, Chen SW, Williamson PTF, et al. Structural basis of membrane disruption and cellular toxicity by alpha-synuclein oligomers. *Science.* 2017;358(6369):1440- 1443.
- 19. Shahnawaz M, Mukherjee A, Pritzkow S, et al. Discriminating alpha-synuclein strains in Parkinson's disease and multiple system atrophy. *Nature.* 2020;578(7794):273-277.
- 20. Nguyen HN, Byers B, Cord B, et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. *Cell Stem Cell.*  2011;8(3):267-280.
- 21. Cookson MR. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. *Nat Rev Neurosci.* 2010;11(12):791-797.
- 22. Watanabe R, Buschauer R, Bohning J, et al. The In Situ Structure of Parkinson's Disease-Linked LRRK2. *Cell.* 2020;182(6):1508-1518 e1516.
- 23. Deniston CK, Salogiannis J, Mathea S, et al. Structure of LRRK2 in Parkinson's disease and model for microtubule interaction. *Nature.* 2020;588(7837):344-349.
- 24. Simuni T, Uribe L, Cho HR, et al. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. *Lancet Neurol.*  2020;19(1):71-80.
- 25. Liu SY, Wile DJ, Fu JF, et al. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study. *Lancet Neurol.* 2018;17(4):309-316.
- 26. Moloney EB, Moskites A, Ferrari EJ, Isacson O, Hallett PJ. The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson's disease patients and increases after lysosomal stress. *Neurobiol Dis.* 2018;120:1-11.
- 27. Diaz-Ortiz ME, Seo Y, Posavi M, et al. GPNMB confers risk for Parkinson's disease through interaction with alpha-synuclein. *Science.* 2022;377(6608):eabk0637.
- 28. Berg D, Borghammer P, Fereshtehnejad SM, et al. Prodromal Parkinson disease subtypes - key to understanding heterogeneity. *Nat Rev Neurol.* 2021;17(6):349-361.
- 29. Carceles-Cordon M, Weintraub D, Chen-Plotkin AS. Cognitive heterogeneity in Parkinson's disease: A mechanistic view. *Neuron.* 2023;111(10):1531-1546.
- 30. Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson's disease. *Lancet Neurol.* 2021;20(5):385-397.
- 31. Weintraub D, Aarsland D, Chaudhuri KR, et al. The neuropsychiatry of Parkinson's disease: advances and challenges. *Lancet Neurol.* 2022;21(1):89-102.
- 32. Grover S, Kumar Sreelatha AA, Pihlstrom L, et al. Genome-wide Association and Meta-analysis of Age at Onset in Parkinson Disease: Evidence From the COURAGE-PD Consortium. *Neurology.* 2022;99(7):e698-e710.
- 33. Li C, Ou R, Chen Y, et al. Genetic Modifiers of Age at Onset for Parkinson's Disease in Asians: A Genome-Wide Association Study. *Mov Disord.* 2021;36(9):2077-2084.
- 34. Sun YM, Yu HL, Zhou XY, et al. Disease Progression in Patients with Parkin-Related Parkinson's Disease in a Longitudinal Cohort. *Mov Disord.* 2021;36(2):442-448.
- 35. Cao LX, Jiang Y, Piao YS, Huang Y. Rapid motor progression of Parkinson's disease associates with clinical and genetic variants. *Front Biosci (Landmark Ed).*  2021;26(12):1503-1512.

- 36. Maple-Grodem J, Dalen I, Tysnes OB, et al. Association of GBA Genotype With Motor and Functional Decline in Patients With Newly Diagnosed Parkinson Disease. *Neurology.* 2021;96(7):e1036-e1044.
- 37. Chen Z, Wu B, Li G, Zhou L, Zhang L, Liu J. MAPT rs17649553 T allele is associated with better verbal memory and higher small-world properties in Parkinson's disease. *Neurobiol Aging.* 2023;129:219-231.
- 38. Caminiti SP, Carli G, Avenali M, Blandini F, Perani D. Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations. *Mov Disord.* 2022;37(1):106-118.
- 39. Jesus S, Huertas I, Bernal-Bernal I, et al. GBA Variants Influence Motor and Non-Motor Features of Parkinson's Disease. *PLoS One.* 2016;11(12):e0167749.
- 40. Saunders-Pullman R, Mirelman A, Alcalay RN, et al. Progression in the LRRK2- Asssociated Parkinson Disease Population. *JAMA Neurol.* 2018;75(3):312-319.
- 41. Trinh J, Zeldenrust FMJ, Huang J, et al. Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review. *Mov Disord.* 2018;33(12):1857-1870.
- 42. Kilarski LL, Pearson JP, Newsway V, et al. Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease. *Mov Disord.* 2012;27(12):1522-1529.
- 43. Kasten M, Hartmann C, Hampf J, et al. Genotype-Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review. *Mov Disord.* 2018;33(5):730-741.
- 44. Bakhit Y, Ibrahim MO, Tesson C, et al. Intrafamilial and interfamilial heterogeneity of PINK1-associated Parkinson's disease in Sudan. *Parkinsonism Relat Disord.*  2023;111:105401.
- 45. Koros C, Stamelou M, Simitsi A, et al. Selective cognitive impairment and hyposmia in p.A53T SNCA PD vs typical PD. *Neurology.* 2018;90(10):e864-e869.
- 46. Petrucci S, Ginevrino M, Trezzi I, et al. GBA-Related Parkinson's Disease: Dissection of Genotype-Phenotype Correlates in a Large Italian Cohort. *Mov Disord.*  2020;35(11):2106-2111.
- 47. Ren J, Zhang R, Pan C, et al. Prevalence and genotype-phenotype correlations of GBA-related Parkinson disease in a large Chinese cohort. *Eur J Neurol.*  2022;29(4):1017-1024.
- 48. Wang G, Huang Y, Chen W, et al. Variants in the SNCA gene associate with motor progression while variants in the MAPT gene associate with the severity of Parkinson's disease. *Parkinsonism Relat Disord.* 2016;24:89-94.
- 49. Si QQ, Yuan YS, Zhi Y, et al. SNCA rs11931074 polymorphism correlates with spontaneous brain activity and motor symptoms in Chinese patients with Parkinson's disease. *J Neural Transm (Vienna).* 2019;126(8):1037-1045.
- 50. Shen YT, Wang JW, Wang M, et al. BST1 rs4698412 allelic variant increases the risk of gait or balance deficits in patients with Parkinson's disease. *CNS Neurosci Ther.*  2019;25(4):422-429.
- 51. Tan MMX, Lawton MA, Jabbari E, et al. Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease. *Mov Disord.*  2021;36(2):424-433.
- 52. Deng X, Xiao B, Allen JC, et al. Parkinson's disease GWAS-linked Park16 carriers show greater motor progression. *J Med Genet.* 2019;56(11):765-768.
- 53. Webb J, Willette AA. Aging modifies the effect of GCH1 RS11158026 on DAT uptake and Parkinson's disease clinical severity. *Neurobiol Aging.* 2017;50:39-46.
- 54. Pu JL, Jin CY, Wang ZX, et al. Apolipoprotein E Genotype Contributes to Motor Progression in Parkinson's Disease. *Mov Disord.* 2022;37(1):196-200.
- 55. Chen Z, Wu B, Li G, Zhou L, Zhang L, Liu J. Parkinson's disease-associated genetic variants synergistically shape brain networks. *medRxiv.*  2023:2022.2012.2025.22283938.
- 56. Chen Z, Wu B, Li G, Zhou L, Zhang L, Liu J. Age and sex differentially shape brain networks in Parkinson's disease. *CNS Neurosci Ther.* 2023;29(7):1907-1922.
- 57. Yue X, Li Z, Li Y, et al. Altered Static and Dynamic Functional Network Connectivity in Post-stroke Cognitive Impairment. *Neurosci Lett.* 2023:137097.
- 58. Lesourd M, Reynaud E, Navarro J, et al. Involvement of the posterior tool processing network during explicit retrieval of action tool and semantic tool knowledge: an fMRI study. *Cereb Cortex.* 2023.
- 59. Chaddock-Heyman L, Weng TB, Kienzler C, et al. Scholastic performance and functional connectivity of brain networks in children. *PLoS One.*  2018;13(1):e0190073.
- 60. Wu GR, Stramaglia S, Chen H, Liao W, Marinazzo D. Mapping the voxel-wise effective connectome in resting state FMRI. *PLoS One.* 2013;8(9):e73670.
- 61. Wang J, Wang X, Xia M, Liao X, Evans A, He Y. GRETNA: a graph theoretical network analysis toolbox for imaging connectomics. *Front Hum Neurosci.*  2015;9:386.
- 62. Rubinov M, Sporns O. Complex network measures of brain connectivity: uses and interpretations. *Neuroimage.* 2010;52(3):1059-1069.
- 63. Wang JH, Zuo XN, Gohel S, Milham MP, Biswal BB, He Y. Graph theoretical analysis of functional brain networks: test-retest evaluation on short- and long-term resting-state functional MRI data. *PLoS One.* 2011;6(7):e21976.
- 64. Zalesky A, Fornito A, Bullmore ET. Network-based statistic: identifying differences in brain networks. *Neuroimage.* 2010;53(4):1197-1207.
- 65. Benjamini Y, Yekutieli D. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society.*  1995;57(1):289-300.
- 66. Szewczyk-Krolikowski K, Tomlinson P, Nithi K, et al. The influence of age and gender on motor and non-motor features of early Parkinson's disease: initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. *Parkinsonism Relat Disord.* 2014;20(1):99-105.
- 67. Luth T, Konig IR, Grunewald A, et al. Age at Onset of LRRK2 p.Gly2019Ser Is Related to Environmental and Lifestyle Factors. *Mov Disord.* 2020;35(10):1854-1858.
- 68. Gabbert C, Konig IR, Luth T, et al. Lifestyle factors and clinical severity of Parkinson's disease. *Sci Rep.* 2023;13(1):9537.
- 69. Lai D, Alipanahi B, Fontanillas P, et al. Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease. *Ann Neurol.* 2021;90(1):76-88.
- 70. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. *J Neurosci.* 2010;30(21):7281-7289.
- 71. Hall S, Surova Y, Ohrfelt A, et al. Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease. *Mov Disord.* 2016;31(6):898-905.
- 72. Engelender S, Isacson O. The Threshold Theory for Parkinson's Disease. *Trends Neurosci.* 2017;40(1):4-14.
- 73. de Franciscis S, Johnson S, Torres JJ. Enhancing neural-network performance via assortativity. *Phys Rev E Stat Nonlin Soft Matter Phys.* 2011;83(3 Pt 2):036114.
- 74. Pechenick DA, Payne JL, Moore JH. The influence of assortativity on the robustness of signal-integration logic in gene regulatory networks. *J Theor Biol.* 2012;296:21-32.
- 75. Roy M, Poria S, Hens C. Assortativity-induced explosive synchronization in a complex neuronal network. *Phys Rev E.* 2021;103(6-1):062307.
- 76. Wang E, Jia Y, Ya Y, et al. Abnormal Topological Organization of Sulcal Depth-Based Structural Covariance Networks in Parkinson's Disease. *Front Aging Neurosci.*  2020;12:575672.
- 77. Vo A, Schindlbeck KA, Nguyen N, et al. Adaptive and pathological connectivity responses in Parkinson's disease brain networks. *Cereb Cortex.* 2023;33(4):917-932.
- 78. Tang Y, Xiao X, Xie H, et al. Altered Functional Brain Connectomes between Sporadic and Familial Parkinson's Patients. *Front Neuroanat.* 2017;11:99.
- 79. Luo N, Sui J, Abrol A, et al. Structural Brain Architectures Match Intrinsic Functional Networks and Vary across Domains: A Study from 15 000+ Individuals. *Cereb Cortex.* 2020.
- 80. Lawrence AJ, Tozer DJ, Stamatakis EA, Markus HS. A comparison of functional and tractography based networks in cerebral small vessel disease. *Neuroimage Clin.*  2018;18:425-432.
- 81. Nestor SM, Misic B, Ramirez J, et al. Small vessel disease is linked to disrupted structural network covariance in Alzheimer's disease. *Alzheimers Dement.*  2017;13(7):749-760.
- 82. Gong G, He Y, Chen ZJ, Evans AC. Convergence and divergence of thickness correlations with diffusion connections across the human cerebral cortex. *Neuroimage.*  2012;59(2):1239-1248.
- 83. van Noort V, Snel B, Huynen MA. The yeast coexpression network has a small-world, scale-free architecture and can be explained by a simple model. *EMBO Rep.*  2004;5(3):280-284.
- 84. Le DH. Network-based ranking methods for prediction of novel disease associated microRNAs. *Comput Biol Chem.* 2015;58:139-148.
- 85. Bork P, Jensen LJ, von Mering C, Ramani AK, Lee I, Marcotte EM. Protein interaction networks from yeast to human. *Curr Opin Struct Biol.* 2004;14(3):292-299.
- 86. Bullmore E, Sporns O. Complex brain networks: graph theoretical analysis of structural and functional systems. *Nat Rev Neurosci.* 2009;10(3):186-198.
- 87. Shin JH, Shin SA, Lee JY, Nam H, Lim JS, Kim YK. Precuneus degeneration and isolated apathy in patients with Parkinson's disease. *Neurosci Lett.* 2017;653:250-257.
- 88. Dusek P, Jech R, Sieger T, et al. Abnormal activity in the precuneus during time perception in Parkinson's disease: an fMRI study. *PLoS One.* 2012;7(1):e29635.
- 89. Thibes RB, Novaes NP, Lucato LT, et al. Altered Functional Connectivity Between Precuneus and Motor Systems in Parkinson's Disease Patients. *Brain Connect.*  2017;7(10):643-647.
- 90. Jia X, Li Y, Li K, Liang P, Fu X. Precuneus Dysfunction in Parkinson's Disease With Mild Cognitive Impairment. *Front Aging Neurosci.* 2018;10:427.
- 91. Shang S, Zhu S, Wu J, et al. Topological disruption of high-order functional networks in cognitively preserved Parkinson's disease. *CNS Neurosci Ther.* 2023;29(2):566-576.
- 92. Wei L, Zhang J, Long Z, et al. Reduced topological efficiency in cortical-basal Ganglia motor network of Parkinson's disease: a resting state fMRI study. *PLoS One.*  2014;9(10):e108124.
- 93. Chen Z, Wu B, Li G, Zhou L, Zhang L, Liu J. BIN3 rs2280104 T allele is associated with excessive daytime sleepiness and altered network topology in Parkinson's disease. *medRxiv.* 2023:2023.2007.2017.23292760.
- 94. Luo CY, Guo XY, Song W, et al. Functional connectome assessed using graph theory in drug-naive Parkinson's disease. *J Neurol.* 2015;262(6):1557-1567.
- 95. Zhang D, Wang J, Liu X, Chen J, Liu B. Aberrant Brain Network Efficiency in Parkinson's Disease Patients with Tremor: A Multi-Modality Study. *Front Aging Neurosci.* 2015;7:169.
- 96. Hou Y, Wei Q, Ou R, Yang J, Gong Q, Shang H. Impaired topographic organization in Parkinson's disease with mild cognitive impairment. *J Neurol Sci.*  2020;414:116861.
- 97. Fang J, Chen H, Cao Z, et al. Impaired brain network architecture in newly diagnosed Parkinson's disease based on graph theoretical analysis. *Neurosci Lett.* 2017;657:151- 158.
- 98. Bejr-Kasem H, Pagonabarraga J, Martinez-Horta S, et al. Disruption of the default mode network and its intrinsic functional connectivity underlies minor hallucinations in Parkinson's disease. *Mov Disord.* 2019;34(1):78-86.
- 99. Chen L, Huang T, Ma D, Chen YC. Altered Default Mode Network Functional Connectivity in Parkinson's Disease: A Resting-State Functional Magnetic Resonance Imaging Study. *Front Neurosci.* 2022;16:905121.
- 100. Szewczyk-Krolikowski K, Menke RA, Rolinski M, et al. Functional connectivity in the basal ganglia network differentiates PD patients from controls. *Neurology.*  2014;83(3):208-214.
- 101. Humphries MD, Obeso JA, Dreyer JK. Insights into Parkinson's disease from computational models of the basal ganglia. *J Neurol Neurosurg Psychiatry.*  2018;89(11):1181-1188.
- 102. Neumann WJ, Schroll H, de Almeida Marcelino AL, et al. Functional segregation of basal ganglia pathways in Parkinson's disease. *Brain.* 2018;141(9):2655-2669.
- 103. Krishna V, Fishman PS, Eisenberg HM, et al. Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinson's Disease. *N Engl J Med.* 2023;388(8):683-693.
- 104. Ramirez-Zamora A, Ostrem JL. Globus Pallidus Interna or Subthalamic Nucleus Deep Brain Stimulation for Parkinson Disease: A Review. *JAMA Neurol.*  2018;75(3):367-372.
- 105. East MP, Laitinen T, Asquith CRM. BCKDK: an emerging kinase target for metabolic diseases and cancer. *Nat Rev Drug Discov.* 2021;20(7):498.
- 106. Xue P, Zeng F, Duan Q, et al. BCKDK of BCAA Catabolism Cross-talking With the MAPK Pathway Promotes Tumorigenesis of Colorectal Cancer. *EBioMedicine.*  2017;20:50-60.
- 107. Tian Q, Yuan P, Quan C, et al. Phosphorylation of BCKDK of BCAA catabolism at Y246 by Src promotes metastasis of colorectal cancer. *Oncogene.* 2020;39(20):3980- 3996.
- 108. Grenier-Larouche T, Coulter Kwee L, Deleye Y, et al. Altered branched-chain alphaketo acid metabolism is a feature of NAFLD in individuals with severe obesity. *JCI Insight.* 2022;7(15).
- 109. Novarino G, El-Fishawy P, Kayserili H, et al. Mutations in BCKD-kinase lead to a potentially treatable form of autism with epilepsy. *Science.* 2012;338(6105):394-397.
- 110. Garcia-Cazorla A, Oyarzabal A, Fort J, et al. Two novel mutations in the BCKDK (branched-chain keto-acid dehydrogenase kinase) gene are responsible for a neurobehavioral deficit in two pediatric unrelated patients. *Hum Mutat.*  2014;35(4):470-477.
- 111. Cheon S, Kaur K, Nijem N, et al. The ubiquitin ligase UBE3B, disrupted in intellectual disability and absent speech, regulates metabolic pathways by targeting BCKDK. *Proc Natl Acad Sci U S A.* 2019;116(9):3662-3667.

- 112. Tangeraas T, Constante JR, Backe PH, et al. BCKDK deficiency: a treatable neurodevelopmental disease amenable to newborn screening. *Brain.*  2023;146(7):3003-3013.
- 113. Yu JY, Cao N, Rau CD, et al. Cell-autonomous effect of cardiomyocyte branchedchain amino acid catabolism in heart failure in mice. *Acta Pharmacol Sin.*  2023;44(7):1380-1390.
- 114. Uddin GM, Zhang L, Shah S, et al. Impaired branched chain amino acid oxidation contributes to cardiac insulin resistance in heart failure. *Cardiovasc Diabetol.*  2019;18(1):86.
- 115. Wang L, Li NN, Lu ZJ, et al. Association of three candidate genetic variants in ACMSD/TMEM163, GPNMB and BCKDK /STX1B with sporadic Parkinson's disease in Han Chinese. *Neurosci Lett.* 2019;703:45-48.
- 116. Heckman MG, Kasanuki K, Diehl NN, et al. Parkinson's disease susceptibility variants and severity of Lewy body pathology. *Parkinsonism Relat Disord.*  2017;44:79-84.
- 117. Dang X, Zhang Z, Luo XJ. Mendelian Randomization Study Using Dopaminergic Neuron-Specific eQTL Nominates Potential Causal Genes for Parkinson's Disease. *Mov Disord.* 2022;37(12):2451-2456.
- 118. Soutar MPM, Melandri D, O'Callaghan B, et al. Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson's disease at 16q11.2 and MAPT H1 loci. *Brain.* 2022;145(12):4349-4367.
- 119. Li CY, Ou RW, Chen YP, et al. Genetic Analysis of ZNF Protein Family Members for Early-Onset Parkinson's Disease in Chinese Population. *Mol Neurobiol.*  2021;58(7):3435-3442.
- 120. Zhang H, Yang L, Feng Q, Fan Y, Zheng H, He Y. Association between VKORC1 gene polymorphisms and ischemic cerebrovascular disease in Chinese Han population. *J Mol Neurosci.* 2014;53(2):166-170.
- 121. Mur J, McCartney DL, Chasman DI, et al. Variation in VKORC1 Is Associated with Vascular Dementia. *J Alzheimers Dis.* 2021;80(3):1329-1337.
- 122. Marioni RE, Harris SE, Zhang Q, et al. GWAS on family history of Alzheimer's disease. *Transl Psychiatry.* 2018;8(1):99.

<b>Clinical variable</b>	<b>GG</b> carriers	<b>A-carriers</b>	<b>GA</b> carriers	<b>AA</b> carriers	<b>GG</b> carriers	GG carriers vs	<b>GG</b> carriers	<b>Multivariate</b>
	$(n = 46)$	$(n = 100)$	$(n = 83)$	$(n = 17)$	<i>vs</i> A-carriers	<b>GA</b> carriers	<i>vs</i> AA carriers	regression analysis
Age, years	$62.25 \pm 7.75$	$60.78 \pm 9.82$	$60.31 \pm 10.17$	$63.06 \pm 7.74$	p > 0.05	p > 0.05	p > 0.05	
Sex (Male/Female)	31/15	62/38	51/32	11/6	p > 0.05	p > 0.05	p > 0.05	
Education, years	$14.91 \pm 2.73$	$15.43 \pm 3.10$	$15.27 \pm 2.97$	$16.24 \pm 3.65$	p > 0.05	p > 0.05	p > 0.05	$\overline{\phantom{a}}$
Disease duration, years	$2.00 \pm 1.50$	$2.05 \pm 2.40$	$2.08 \pm 2.57$	$1.92 \pm 1.30$	p > 0.05	p > 0.05	p > 0.05	
<b>HY</b>	$1.68 \pm 0.47$	$1.66 \pm 0.52$	$1.65 \pm 0.53$	$1.71 \pm 0.47$	p > 0.05	p > 0.05	p > 0.05	$\beta = -0.0012, p > 0.05$
Tremor	$4.46 \pm 3.68$	$3.54 \pm 3.03$	$3.51 \pm 3.06$	$3.65 \pm 2.98$	p > 0.05	p > 0.05	p > 0.05	$\beta = -0.6271, p > 0.025$
Rigidity	$5.32 \pm 2.99$	$3.83 \pm 2.62$	$3.90 \pm 2.65$	$3.47 \pm 2.53$	p < 0.01	p < 0.01	p < 0.05	$\beta = -1.0410, p < 0.04$
<b>UPDRS-III</b>	$24.52 \pm 10.68$	$19.22 \pm 8.71$	$19.29 \pm 9.01$	$18.88 \pm 7.29$	p < 0.01	p < 0.01	p < 0.05	$\beta = -3.3540, p < 0.0$

**Table 1 The demographic and clinical data for different genotype groups of** *BCKDK* **rs14235** 

The data were shown as the mean  $\pm$  standard deviation (SD). The motor function examination was assessed in ON state. Unpaired t-test (GG carriers *vs* A-carriers) and one-way ANOVA followed by FDR correction (GG carriers *vs* GA carrier *vs* AA carriers) were used to compare the continuous variables among different genotype groups of  $BCKDK$  rs14235.  $\chi^2$  test was used for the comparisons of categorical variables (Sex). Abbreviations: HY, Hoehn & Yahr stage; UPDRS-III, Unified Parkinson' s Disease Rating Scale Part III.



**Figure 1. Group differences of motor assessments between GG carriers and A-carriers of PD patients.** (A) A-carriers exhibited lower rigidity scores compared to GG carriers. (B) GA and AA carriers showed lower rigidity scores compared to GG carriers. (C) A-carriers presented lower UPDRS-III scores compared to GG carriers. (D) GA and AA carriers showed lower UPDRS-III scores compared to GG carriers. Unpaired t-test (GG carriers *vs* A-carriers) and one-way ANOVA test followed by FDR corrections (GG carriers *vs* GA carrier *vs* AA carriers) were used.  $p < 0.05$  was considered statistically significant. Abbreviations: UPDRS-III, Unified Parkinson's Disease Rating Scale part III.



**Figure 2. Group differences of structural network metrics among GG, GA, and AA carriers.** (A-C) Group differences in assortativity (A), small-worldness γ (B), and smallworldness σ (C) among GG, GA, and AA carriers (FDR-corrected  $p < 0.05$ , Two-way ANOVA test). (D-I) Group differences in nodal betweenness centrality (D), degree centrality (E), Cp (F), efficiency (G), local efficiency (H), and SPL (I) among GG, GA, and AA carriers (FDR-corrected  $p < 0.05$ , Two-way ANOVA test). Two-way ANOVA test followed by FDR corrections (GG carriers *vs* GA carrier *vs* AA carriers) were used.  $p < 0.05$  was considered statistically significant. Abbreviations: Cp, Clustering coefficient;  $\gamma$ , normalized clustering coefficient; σ, small worldness; SPL, shortest path length.



**Figure 3. Group differences of functional network metrics among GG, GA, and AA carriers.** (A-B) Group differences in global efficiency (A) and local efficiency (B) among GG, GA, and AA carriers (FDR-corrected *p* < 0.05, Two-way ANOVA test). (D-I) Group differences in nodal betweenness centrality (C), degree centrality (D), Cp (E), efficiency (F), local efficiency (G), and SPL (H) among GG, GA, and AA carriers (FDR-corrected *p* < 0.05, Two-way ANOVA test). Two-way ANOVA test followed by FDR corrections (GG carriers

*vs* GA carrier *vs* AA carriers) were used. *p* < 0.05 was considered statistically significant.

Abbreviations: Cp, Clustering coefficient; SPL, shortest path length.



**Figure 4. Mediation analysis suggested structural network metrics mediated the effects of** *BCKDK* **rs14235 on motor assessments of PD patients.** (A) AUC of assortativity was negatively associated with the rigidity scores of PD patients ( $p < 0.05$  in both Pearson correlation analysis and multivariate regression analysis). (B) Nodal SPL of right pallidum was positively associated with UPDRS-III scores in PD patients ( $p < 0.05$  in both Pearson correlation analysis and multivariate regression analysis). (C) AUC of assortativity mediated the effects of *BCKDK* rs14235 on rigidity scores. (D) Nodal SPL of right pallidum mediated the effects of *BCKDK* rs14235 on UPDRS-III scores. The association analysis between network metrics and scores of motor assessments was conducted by Pearson correlation method and multivariate regression analysis with age, sex, disease duration, and years of education as covariates. During the mediation analysis, age, sex, disease duration, and years of education were included as covariates.  $p < 0.05$  was considered statistically significant. Abbreviations: AUC, Area under curve; UPDRS-III, Unified Parkinson's Disease Rating Scale part III; SPL, shortest path length.